South Korea Hemato Oncology Market Insight
Published: 31 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
With a projected CAGR of 8.75% from 2025 to 2035, the South Korean hemato oncology market is propelled by increasing blood cancer prevalence and cutting-edge treatments.
South Korea Hemato Oncology Market Insights Forecasts to 2035
- The South Korea Hemato Oncology Market Size Was Estimated USD 1.18 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 8.75% from 2025 to 2035
- The South Korea Hemato Oncology Market Size is Expected to rise around USD 2.73 Billion by 2035
Notable Insights for the South Korea Hemato Oncology Market
- According to the segmentation of cancer types, lymphoma generated the most revenue in 2024 and held a significant portion of the market for hemato oncology testing in South Korea.
- Chemotherapy is still the mainstay of treatment in South Korea, but immunotherapy and targeted therapy are becoming increasingly popular based on therapy segmentation.
- Leukemia, lymphoma, and myeloma are examples of hematologic malignancies, according to South Korean government data, and their increasing incidence rates are fueling the country's need for sophisticated diagnostics and therapies.
- South Korea's biologics market is expected to reach USD 23.17 billion by 2035, accounting for 0.9% of the global hemato oncology testing market revenue in 2024.
Download the eBook (ToC)
Research Methodologies Used to Analyze the South Korea Hemato Oncology Market
The South Korea hemato oncology market is studied by talking to people in the field and looking at what has been written about it. This means people do interviews with companies that make medicine companies that work with living things, hospitals, cancer treatment centers, doctors who treat blood diseases, doctors who treat cancer people who sell things and experts in the field. The South Korea hemato oncology market is analyzed to see how it will grow and what the prices of things will be, like. The South Korea hemato oncology market is important to understand so that people can make decisions about it.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors do a lot of research to understand what is happening in the market. They look closely at what's going on in each industry. They also compare companies to see how they are doing. They try to figure out what will happen in the future with trends and they use data to help businesses make decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea hemato oncology market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Hemato Oncology Market
- NGeneBio
- GC Cell
- GI Innovation
- PharmGen Science
- NOBO Medicine
- Roche Holding AG
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Qiagen NV
- Illumina Inc.
Recent Developments:
- In October 2025, through cooperative clinical research projects, I worked with biotechnology partners to advance immuno-oncology pipeline candidates for hematologic cancer treatment.
- In September 2025, a sophisticated next-generation sequencing panel for hematologic malignancies was introduced, enhancing precision oncology diagnosis and individualized treatment planning in South Korean medical facilities.
Market Segmentation:
South Korea Hemato Oncology Market, By Cancer Type
- Leukemia
- Lymphoma
- Myeloma
- Other Cancers
South Korea Hemato Oncology Market, By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Stem Cell Transplant
- Other Therapies
South Korea Hemato Oncology Market, By End-User
- Hospitals
- Specialty Clinics
- Research Institutes
- Diagnostic Laboratories
Expert Views:
The South Korea hemato oncology market will get big by 2035. This is because more people are getting blood cancer. Doctors are also getting better at using medicine that is just right for each person. The hospitals and clinics in South Korea are very good. This will help people get better and it will make the South Korea hemato oncology market even bigger, in the long run.
Author: Govind and Krishna By Decisions Advisors and Consulting